Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMBS | P08397 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2731157 | 1.00 | HMBS (0.41) | HMBSDAOCYP1A2CYP3A4LMNA | |
| SCHEMBL1973156 | 0.75 | DAO (0.36) | DAOKMT2A | |
| SCHEMBL1970318 | 0.75 | KDM1A (0.33) | — | |
| SCHEMBL2730789 | 0.75 | DAO (0.36) | DAOKMT2A | |
| SCHEMBL10207797 | 0.75 | SMN1; SMN2 (0.33) | GAA | |
| SCHEMBL279417 | 0.74 | — | — | |
| SCHEMBL1975131 | 0.71 | NPSR1 (0.37) | CYP1A2CYP3A4 | |
| SCHEMBL13692394 | 0.67 | — | — | |
| SCHEMBL2477676 | 0.64 | PRSS1 (0.52) | CYP1A2CYP3A4LMNAGFERKMT2A | |
| SCHEMBL25919609 | 0.64 | HMBS (0.42) | HMBSLMNAGFERKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632469-A2 | TRICYCLIC MGLUR5 RECEPTOR MODULATORS | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130210804-A1 | TRICYCLIC MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2013-08-15 | — | — | US | disclosed |
| US-20130210804-A1 | TRICYCLIC MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2013-08-15 | — | — | US | disclosed |
| WO-2012061019-A2 | TRICYCLIC MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2012-05-10 | — | — | WO | disclosed |
| CN-101218234-B | Phenyl-3-{(3-(1H-pyrrol-2-yl)-[1,2,4]oxadiazol-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2011-12-14 | — | — | CN | disclosed |
| EP-1912979-B1 | PHENYL-{3-(3-(1H-PYRROL-2-YL)-[1,2,4]OXADIAZOL-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2011-06-22 | — | — | EP | disclosed |
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | ADDEX PHARMA SA (CH) | 2009-08-13 | — | — | US | disclosed |
| CN-101218234-A | Phenyl-3-{(3-(1H-pyrrol-2-yl)-[1,2,4]oxadiazol-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA (CH) | 2008-07-09 | — | — | CN | disclosed |
| EP-1912979-A2 | PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1,2,4]OXADIAZOL-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2008-04-23 | — | — | EP | disclosed |
| WO-2006123257-A2 | PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1, 2 , 4]0XADIAZ0L-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210804-A1 | TRICYCLIC MGLUR5 RECEPTOR MODULATORS | GRM5, GRM1, GRM2 | HMBS 2936/4885DAO 1139/4885CYP1A2 4102/4885 |
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | GRM5, GRIK5, GRM2 | HMBS 1555/4885DAO 3141/4885CYP1A2 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.